Cytochrome P450 2D6 Genotyping: Potential Role in Improving Treatment Outcomes in Psychiatric Disorders

Kirchheiner, Julia; Rodriguez-Antona, Cristina
March 2009
CNS Drugs;2009, Vol. 23 Issue 3, p181
Academic Journal
The specific reaction toward a given drug varies a lot between individuals and, for many drugs, pharmacogenetic polymorphisms are known to affect biotransformation and clinical outcome. Estimation of the individual's drugmetabolizing capacity can be undertaken by genotyping drug-metabolizing enzymes involved in the respective drug metabolism. Consequences that arise from genotyping may be the adjustment of dose according to genotype, choice of therapeutic strategy, or even choice of drug. One of the first fields where the clinical application of pharmacogenetics may be used is in that of antipsychotic and antidepressant drug treatment because there is a special need for individualized therapy in psychiatry. The pharmacokinetics of many TCAs, some SSRIs and other antidepressant drugs is significantly altered by polymorphisms; however, some controversy still exists as to whether therapeutic efficacy may be improved and/or adverse events can be prevented by genetically driven adjustment of drug dosage. Pharmacogenetic diagnostics may be an important factor in individualizing drug treatment according to the genetic make-up of the patients. However, routine application of pharmacogenetic dose adjustment in clinical practice requires prospective validation.


Related Articles

  • Modeling Biotransformation Reactions by Combined Quantum Mechanical / Molecular Mechanical Approaches: From Structure to Activity. L. Ridder; A.J. Mulholland // Current Topics in Medicinal Chemistry;Jul2003, Vol. 3 Issue 11, p1241 

    An overview of the combined quantum mechanical / molecular mechanical (QM / MM) approach and its application to studies of biotransformation enzymes and drug metabolism is given. Theoretical methods to simulate enzymatic reactions have rapidly developed during the last decade. In particular, QM...

  • Tumoral Drug Metabolism: Perspectives and Therapeutic Implications. M.M. Doherty; M. Michael // Current Drug Metabolism;Apr2003, Vol. 4 Issue 2, p131 

    Drug metabolising enzymes (DME) in tumors are capable of biotransforming a variety of xenobiotics. Over a long period of time, many studies have reported the presence of DME in tumors, however quantitation and sampling techniques and heterogeneous patient populations have resulted in many...

  • BROMELAIN: AN ANTI-INFLAMMATORY AGENT. Seligman, Bert // Angiology;Nov1962, Vol. 13 Issue 11, p508 

    Discusses the pharmacological characteristics of bromelain. Functions of bromelain; Arterial diseases that can be manage with bromelain; Indications of bromelain.

  • Foreign Compounds and Intermediary Metabolism: Sulfoxidation Bridges the Divide. Mitchell, S. C.; Steventon, G. B. // Current Drug Metabolism;Mar2009, Vol. 10 Issue 3, p220 

    It is widely appreciated that as a xenobiotic travels through an organism and interacts with the biochemical machinery of a living system, it most probably will undergo a number of metabolic alterations usually leading to a cluster of differing chemical species. Indeed, the modern 'metabonomic'...

  • Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases. Dupret, Jean-Marie; Dairou, Julien; Atmane, Noureddine; Rodrigues-Lima, Fernando // Current Pharmacogenomics;Dec2004, Vol. 2 Issue 4, p333 

    Xenobiotic-metabolizing enzymes (XME) are responsible for the biotransformation of a vast range of compounds. Arylamine N-acetyltransferases (NAT) are XME responsible for the acetylation of many arylamine and heterocyclic amines. They therefore, play an important role in the detoxification and...

  • cumulative drug action.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p556 

    A definition of the medical term "cumulative drug action," which refers to the action of repeated doses of drugs that are not immediately removed from the body, is presented.

  • Multiple Species Metabolism of PHA-568487, A Selective a7 Nicotinic Acetylcholine Receptor Agonist. Shilliday, F. Barclay; Walker, Daniel P.; Chungang Gu; Xiaojun Fang; Thornburgh, Bruce; Fate, Gwendolyn D.; Daniels, J. Scott // Drug Metabolism Letters;Aug2010, Vol. 4 Issue 3, p163 

    The quinuclidine PHA-0568487(1) is an agonist of the alpha7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability. The drug metabolites of 1 in nonclinical...

  • Accurate Mass: Why It's the Best Solution for Metabolite Identification in Discovery, Development, and Clinical Applications. Tiller, Philip R. // Spectroscopy;Mar2012 Supplement, p12 

    The article discusses on significance of analysis of accurate mass over nominal-mass in identification of metabolites. It mentions that accurate mass-based analysis helps in differentiation between analytes of interest and the matrix, understanding nature of biotransformation and in determining...

  • Pharmacogenetics of Phase I and Phase II Drug Metabolism. Crettol, Severine; Petrovic, Nenad; Murray, Michael // Current Pharmaceutical Design;1/11/2010, Vol. 16 Issue 2, p204 

    Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics